2-(nicotinamido)ethyl retinoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-(nicotinamido)ethyl retinoate
• 英文别名: 2-(pyridine-3-carbonylamino)ethyl (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate
• 化学式: C₂₈H₃₆N₂O₃
• 分子量: 448.605
• InChiKey: NWHSBVFSHZEZBY-HOLHFGSJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  33
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  68.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-(2-羟乙基)烟酰胺 、 维A酸 在 4-二甲氨基吡啶 、 1-丙基磷酸酐 、 三乙胺 作用下， 以 乙酸乙酯 为溶剂， 反应 15.0h， 以1 g的产率得到2-(nicotinamido)ethyl retinoate
  参考文献：
  名称：

  [EN] RETINOID DERIVATIVES AND PROCESS FOR THEIR PREPARATION
  [FR] DÉRIVÉS RÉTINOÏDES ET PROCÉDÉ POUR LES PRÉPARER

  摘要：

  描述了一种新型的维甲酸衍生物及其制备方法。

  公开号：

  WO2014204390A1

文献信息

• RETINOID DERIVATIVES AND PROCESS FOR THEIR PREPARATION
  申请人：SELEGO AB

  公开号：US20160136076A1

  公开（公告）日：2016-05-19

  Novel retinoic acid derivatives and a process for their preparation are described.

  本发明涉及新型维甲酸衍生物及其制备方法。
• Retinaldehyde containing compositions and methods of use
  申请人：RODAN & FIELDS, LLC

  公开号：US11318077B2

  公开（公告）日：2022-05-03

  This disclosure is directed to compositions comprised of retinaldehyde, one or more skin conditioning agents, and, optionally, one or more additional retinoids. This disclosure is directed. Embodiments are also directed to compositions comprised of retinaldehyde, one or more peptides, one or more skin conditioning agents, one or more calcium containing agents, and, optionally, one or more additional retinoids. Embodiments are also directed to compositions comprised of retinaldehyde, one or more peptides, one or more skin conditioning agents, one or more calcium containing agents, and, optionally, one or more additional retinoids. Additional embodiments disclose methods for treating the skin wherein a characteristic of the skin is improved, the characteristics include firmness, elasticity, fine lines and wrinkles, skin texture, dullness, dyschromia, skin tone, reduction or elimination of acne, and any combination thereof. This disclosure is also directed to kits used for treating the skin with the compositions described herein.

  本公开涉及由视黄醛、一种或多种皮肤调理剂，以及可选的一种或多种额外的维甲酸组成的组合物。本公开涉及的组合物包括视黄醛、一种或多种皮肤调理剂、以及一种或多种额外的维甲酸。本发明的实施方案还涉及由视黄醛、一种或多种肽、一种或多种皮肤调理剂、一种或多种含钙制剂以及可选的一种或多种额外的维甲酸组成的组合物。本发明还涉及由视黄醛、一种或多种肽、一种或多种皮肤调理剂、一种或多种含钙制剂以及一种或多种额外的维甲酸组成的组合物。其他实施方案公开了治疗皮肤的方法，其中皮肤的特征得到了改善，这些特征包括紧致度、弹性、细纹和皱纹、肤质、暗沉、色素沉着、肤色、减少或消除痤疮，以及它们的任意组合。本公开还涉及用本文所述组合物治疗皮肤的试剂盒。
• RETINALDEHYDE CONTAINING COMPOSITIONS AND METHODS OF USE
  申请人：RODAN & FIELDS, LLC

  公开号：US20190099340A1

  公开（公告）日：2019-04-04

  This disclosure is directed to compositions comprised of retinaldehyde, one or more skin conditioning agents, and, optionally, one or more additional retinoids. This disclosure is directed. Embodiments are also directed to compositions comprised of retinaldehyde, one or more peptides, one or more skin conditioning agents, one or more calcium containing agents, and, optionally, one or more additional retinoids. Embodiments are also directed to compositions comprised of retinaldehyde, one or more peptides, one or more skin conditioning agents, one or more calcium containing agents, and, optionally, one or more additional retinoids. Additional embodiments disclose methods for treating the skin wherein a characteristic of the skin is improved, the characteristics include firmness, elasticity, fine lines and wrinkles, skin texture, dullness, dyschromia, skin tone, reduction or elimination of acne, and any combination thereof. This disclosure is also directed to kits used for treating the skin with the compositions described herein.
• COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS
  申请人：Orbus Therapeutics, Inc.

  公开号：US20190133985A1

  公开（公告）日：2019-05-09

  Eflornithine is an agent that can be used to treat glioma, especially glioma of WHO Grade II or Grade III such as anaplastic glioma. Eflornithine can suppress or prevent mutations in glioma which can cause the glioma to progress to a higher grade. Compositions and methods can include eflornithine or a derivative or analog of eflornithine, together with other agents such as conventional anti-neoplastic agents for treatment of glioma, inhibitors of polyamine transport, polyamine analogs, or S-adenosylmethionine decarboxylase inhibitors. Eflornithine or derivatives or analogs thereof can also be used to treat a range of non-glioma malignancies, including both malignancies of the central nervous system and other malignancies.
• USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN
  申请人：Fabius Biotechnology

  公开号：US20210338558A1

  公开（公告）日：2021-11-04

  The present invention addresses the need for an improved delivery system that is able to specifically target the skin for improved bioavailability and minimization of side effects resulting from administration of the active ingredient or ingredients. One aspect of the present invention is a targeting composition comprising: (1) a skin care agent or an agent that is a cosmeceutical agent; (2) an intermediate release linker bound to the skin care agent or cosmeceutical agent; (3) a targeting moiety bound to the intermediate release linker, the targeting moiety for binding the targeting composition to native collagen fibers; and (4) optionally, a carrier component to enhance delivery to the skin. The present invention also describes methods of use of these targeting compositions.